Bioxytran (BIXT) News Today $0.10 0.00 (0.00%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisChartEarningsFinancialsSEC FilingsShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period NRx Pharmaceuticals added to Emerging Growth Conference 76 on October 31 and Update to ScheduleOctober 31, 2024 | markets.businessinsider.comBioxytran Expands Portfolio with NDPD Pharma AcquisitionOctober 29, 2024 | msn.comDIAM:CA Star Diamond CorporationSeptember 21, 2024 | seekingalpha.comBioxytran, Inc. (BIXT)August 29, 2024 | finance.yahoo.comBioxytran Launches Joint Venture with the Heme Foundation for Development of Universal Oxygen CarrierJuly 18, 2024 | globenewswire.comBioxytran's Advisor Releases Book on Hyperbaric Oxygenation Related to Stroke & Alzheimer's PatientsJune 27, 2024 | globenewswire.comBIXT: Carbohydrate Drug Design in the Fight Against VirusesMarch 20, 2024 | msn.comBioxytran Announces Preprint of Shingles Case Study Showing Clearance Using a Topical Galectin-3 AntagonistMarch 6, 2024 | globenewswire.comBioxytran’s Oral Antiviral Drug to Enter Dose Optimization Clinical Trial for COVID-19February 21, 2024 | finance.yahoo.comBioxytran's Oral Antiviral Drug to Enter Dose Optimization Clinical Trial for COVID-19February 21, 2024 | globenewswire.comBioxytran Gets Broad Patent Coverage on 60+ VirusesOctober 24, 2023 | finance.yahoo.comBioxytran Announces Broad Spectrum Antiviral Activity Highlighted in ProLectin-MSeptember 14, 2023 | finance.yahoo.comBioxytran Received IND Application by the FDA for Clinical Trials with ProLectin-M to Treat COVID-19 patientsSeptember 6, 2023 | benzinga.comFDA grants clearance to Bioxytran’s IND for Covid-19 trial initiationAugust 25, 2023 | msn.comBioxytran Announces FDA Clearance of its IND Application for ProLectin-M in Clinical TrialsAugust 24, 2023 | finance.yahoo.comBioxytran Initiates a Registrational Trial of Oral ProLectin-M for Mild to Moderate COVID-19 PatientsAugust 8, 2023 | finance.yahoo.comBioxytran Names Leslie Ajayi as Interim CMO and Head of the Medical Advisory BoardJuly 31, 2023 | finance.yahoo.comBioxytran Peer-Reviewed Journal in "Vaccines" Contains Mechanism Capable of Targeting Future COVID-19 MutationsJune 27, 2023 | it.tmcnet.comBioxytran Peer-Reviewed Journal in “Vaccines” Contains Mechanism Capable of Targeting Future COVID-19 MutationsJune 27, 2023 | finance.yahoo.comBioxytran expands institutional investor base with $0.5M equity investmentJune 12, 2023 | msn.comBioxytran Expands Institutional Investor Base with an additional $500,000 Equity InvestmentJune 12, 2023 | finance.yahoo.comBioxytran Tests Acellular Oxygen Carrier BXT-25 in Pre-Clinical TrialsApril 19, 2023 | finance.yahoo.comBioxytran Announces Positive Phase 2 Trial Results were Featured in "Vaccines" a Peer-Reviewed JournalMarch 29, 2023 | tmcnet.comBioxytran Announces Positive Phase 2 Trial Results were Featured in “Vaccines” a Peer-Reviewed JournalMarch 29, 2023 | finance.yahoo.comBioxytran, Inc. (BIXT) Stock Historical Prices & Data - Yahoo FinanceMarch 6, 2023 | finance.yahoo.comProLectin-M Demonstrates Significant Activity Against Influenza and Respiratory Syncytial VirusFebruary 28, 2023 | finance.yahoo.comNature Reviews Drug Discovery Article Offers Independent Support for ProLectin-I in Fibrosis and ProLectin-M as an Antiviral DrugFebruary 22, 2023 | finance.yahoo.comBioxytran to Appear on ClearThink IR’s Virtual Live EventFebruary 14, 2023 | finance.yahoo.comBioxytran drug candidates ProLectin-M and ProLectin-I progressing as COVID-19 treatmentsFebruary 8, 2023 | proactiveinvestors.comBioxytran Receives Approval to Initiate Trials with ProLectin-IFebruary 6, 2023 | finance.yahoo.comBioxytran Shares Rise 20% on Trial Results for Covid-19 DrugDecember 28, 2022 | marketwatch.comBioxytran chewable drug for COVID-19 meets phase 2 trial's goalsDecember 28, 2022 | msn.comCrystal Research Update Highlights 100% Responders Rate in Mild to Moderate COVID-19 TrialDecember 28, 2022 | finance.yahoo.comBioxytran Establishes Indian Subsidiary in Preparation of CommercializationDecember 14, 2022 | finance.yahoo.comBioxytran Interview at the Emerging Growth ConferenceDecember 12, 2022 | finance.yahoo.comBioxytran Gets Approval In India To Optimize Dosage In COVID-19 PatientsDecember 8, 2022 | markets.businessinsider.comBioxytran Receives Approval to Optimize Dosage in COVID-19 PatientsDecember 8, 2022 | finance.yahoo.comBioxytran, Inc. Announces the Reinitiation of Coverage of Its Stock by Avise AnalyticsNovember 22, 2022 | finance.yahoo.comFinancialnewsmedia.com: While COVID-19 Drags On, Biotechs Introduce New Treatments & Vaccines to Combat SubvariantsNovember 16, 2022 | finanznachrichten.deBIOXYTRAN Announces Positive Mid-stage Study Results Of Galectin Antagonist In Covid PatientsNovember 16, 2022 | markets.businessinsider.comBioxytran Releases Positive Top-line Results from Phase 2 Trial of Galectin Antagonist on COVID-19 Patients in medRxiv Pre-printNovember 16, 2022 | finance.yahoo.comBioxytran Scientific Advisor Releases New Book on Brain MetabolismOctober 25, 2022 | finance.yahoo.comEnding The Pandemic Cycle - Bioxytran’s (BIXT) Galectin ApproachSeptember 16, 2022 | seekingalpha.comBIXT.PK - Bioxytran Inc | Stock Price & Latest News | ReutersAugust 17, 2022 | reuters.comNovel Carbohydrate Antiviral Drug Candidate Acts Through Galectin Inhibition to Block SARS-CoV-2 CoronavirusAugust 1, 2022 | finance.yahoo.comBIXT Real-Time QuotesJanuary 24, 2022 | nasdaq.com Get Bioxytran News Delivered to You Automatically Sign up to receive the latest news and ratings for BIXT and its competitors with MarketBeat's FREE daily newsletter. Email Address Election warning coming true… (Ad)If you missed it, my emergency election broadcast is now available - watch it before it's too late. Click here to watch it now. BIXT Media Mentions By Week BIXT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BIXT News Sentiment▼0.000.47▲Average Medical News Sentiment BIXT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BIXT Articles This Week▼00▲BIXT Articles Average Week Get Bioxytran News Delivered to You Automatically Sign up to receive the latest news and ratings for BIXT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Clene News Today Passage Bio News Today ImmuCell News Today Estrella Immunopharma News Today Acasti Pharma News Today ProMIS Neurosciences News Today LianBio News Today HCW Biologics News Today Surrozen News Today Lantern Pharma News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:BIXT) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bioxytran, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bioxytran With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
